Catalyst Pharmaceuticals, Inc.
CPRX
Rankning i aktier
#4178
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Aktiekurs
$31.49
Senast synkroniserad: 2026-07-21
Marknadsvärde
$3.85B
Förändring (1 dag)
0.00%
Förändring (1 år)
46.94%
Land
US
Handel Catalyst Pharmaceuticals, Inc. (CPRX)
Kategori
Healthcare
Antal utestående aktier för Catalyst Pharmaceuticals, Inc. (CPRX)
Antal utestående aktier per March 2026: 122.25M
Enligt de senaste finansiella rapporterna och aktiekursen för Catalyst Pharmaceuticals, Inc. är det aktuella antalet utestående aktier 122.25M. I slutet av December 2023 hade företaget 106.28M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Catalyst Pharmaceuticals, Inc. (CPRX) från 2002 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 122.25M | 3.20% |
| 2024 | 118.46M | 11.46% |
| 2023 | 106.28M | 2.81% |
| 2022 | 103.37M | 0.00% |
| 2021 | 103.38M | -0.13% |
| 2020 | 103.51M | 0.55% |
| 2019 | 102.94M | 0.30% |
| 2018 | 102.63M | 19.62% |
| 2017 | 85.80M | 3.53% |
| 2016 | 82.88M | 2.49% |
| 2015 | 80.86M | 26.06% |
| 2014 | 64.14M | 41.12% |
| 2013 | 45.45M | 51.34% |
| 2012 | 30.03M | 38.22% |
| 2011 | 21.73M | 16.94% |
| 2010 | 18.58M | 23.32% |
| 2009 | 15.07M | 15.78% |
| 2008 | 13.01M | 3.89% |
| 2007 | 12.53M | 62.93% |
| 2006 | 7.69M | 23.90% |
| 2005 | 6.20M | 112.61% |
| 2004 | 2.92M | 0.00% |
| 2003 | 2.92M | 23.73% |
| 2002 | 2.36M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 107.68% |
US
|
|
| 396.00M | 223.92% |
US
|
|
| 478.91M | 291.73% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -49.13% |
NL
|
